A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

NCT ID: NCT06976437

Last Updated: 2025-07-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-06
• Study Completion Date: 2027-12-30

Brief Summary

A single arm, open-label pilot study is designed to determine the safety and efficacy of CD19 and B-cell maturation antigen (BCMA) targeted allogenic CAR-T cells (RN1101) in patients with relapsed/refractory B-cell or plasma cell-derived malignant tumors. 21 patients are planned to be enrolled in the dose-escalation trial. The primary objective of the study is to evaluation of the safety and feasibility of RN1101 for the treatment of relapsed/refractory B-cell or plasma cell-derived malignant tumors. The secondary objective is to evaluate the efficacy of RN1101 for the treatment of relapsed/refractory B-cell or plasma cell-derived malignant tumors. The exploratory objective is to evaluate expansion, persistence and ability of RN1101 to deplete CD19 or BCMA positive cells in patients with relapsed/refractory B-cell or plasma cell-derived malignant tumors.

Conditions

B Cell Lymphoma; Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RN1101 treatment

CD19+ or BCMA+ r/r B Cell lymphoma or multiple myeloma (MM) patients to be treated with a single dose of RN1101 cells.

Group Type: EXPERIMENTAL

RN1101 injection

Intervention Type: DRUG

RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA. A single infusion of CAR-T cells will be administered intravenously.

Interventions

RN1101 injection

RN1101 injection is an allogenic CAR-T targeted CD19 and BCMA. A single infusion of CAR-T cells will be administered intravenously.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Willingness to participate in the trial and provision of signed informed consent.

2. Patients diagnosed with B-lymphocyte or plasma cell-derived malignancies as per the 2017 revised WHO criteria, including acute B-lymphoblastic leukemia (B-ALL), and mature B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), mantle cell lymphoma (MCL), multiple myeloma (MM), etc.

3. Refractory or recurrent B-lymphocyte or plasma cell-derived malignancies, defined as failure to achieve complete remission after standard treatment, or relapse during follow-up after achieving remission with first-line or salvage therapy.

4. Patients with B-cell acute lymphoblastic leukemia (ALL) who have achieved hematologic remission but have persistent minimal residual disease (MRD).

5. According to the revised International Working Group (IWG) criteria, relapsed/refractory lymphoma patients must have at least one measurable lesion with a longest diameter ≥1.5 cm.

6. 18 Years and older, regardless of gender.

7. An expected survival of ≥12 weeks.

8. Serum total bilirubin level < twice the upper limit of normal, serum creatinine level < upper limit of normal, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < three times the upper limit of normal.

9. Absolute neutrophil count ≥0.5×10⁹/L, platelets ≥20×10⁹/L; for B-lymphocyte malignancies with definitive bone marrow involvement, no requirements for neutrophil and platelet counts.

10. ECOG performance status of 0 - 2.

11. Left ventricular ejection fraction (LVEF) ≥50% and no pericardial effusion.

12. At least 2 weeks have passed since the last treatment (radiotherapy, chemotherapy, monoclonal antibody therapy, or other treatments).

Exclusion Criteria

1. Known allergies, hypersensitivity, intolerance, or contraindications to CD19/BCMA allogenic CAR-T or any components of the trial drugs (including fludarabine, cyclophosphamide, and rituximab), or a history of severe allergic reactions.

2. Recurrence after allogeneic hematopoietic stem cell transplantation with active graft - versus - host disease (GVHD) requiring steroid or immunosuppressive therapy.

3. Severe active infection.

4. Acquired or congenital immunodeficiency.

5. New York Heart Association (NYHA) Class Ⅲ or Ⅳ heart failure.

6. History of epilepsy or other central nervous system diseases.

7. Lymphoma with extranodal involvement of the brain, lungs, or gastrointestinal tract.

8. Other primary cancers, except:

1. Non-melanoma skin cancer (e.g., basal cell carcinoma) cured by resection.

2. Carcinoma in situ (e.g., cervical, bladder, or breast cancer) cured.

9. Systemic high-dose steroids within 2 weeks before treatment.

10. Pregnant, breastfeeding, or plans to become pregnant within 6 months.

11. Participation in another clinical trial within the past month.

12. Any situation the investigator deems may raise risks or interfere with trial results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rui Therapeutics Co., Ltd

INDUSTRY

Sponsor Role: collaborator

Allorunning Therapeutics

INDUSTRY

Sponsor Role: collaborator

YANRU WANG

OTHER

Sponsor Role: lead

Responsible Party

YANRU WANG

Doctor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Affiliated Hospital of Jiangsu University

Zhenjiang, Jiangsu, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiaoming Fei

Role: CONTACT

feixiaomingujs@aliyun.com

+86-1381512462752

Facility Contacts

Xiaoming Fei, PhD

Role: primary

feixiaomingujs@aliyun.com

086-1381512462752

Other Identifiers

RunNing

Identifier Type: -

Identifier Source: org_study_id